First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Authors

  • Selin Aktürk Esen Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
  • Yakup Ergun Department of Medical Oncology, Batman Training And Research Hospital, Batman, Turkey https://orcid.org/0000-0003-4784-6743
  • Cihan Erol Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0003-3155-8798
  • Rukiye Arikan Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey https://orcid.org/0000-0003-2688-1515
  • Muhammed Muhiddin Er Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey https://orcid.org/0000-0002-0583-0295
  • Muhammed Mustafa Atci Department of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, Turkey
  • Atakan Topçu Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University Istanbul, Turkey https://orcid.org/0000-0002-3634-4820
  • Gökhan Uçar Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0002-7649-1075
  • Baran Akagündüz Department of Medical Oncology, Erzincan Binali Yildirim University, Erzincan, Turkey
  • Musa Bariş Aykan Department of Medical Oncology, Gulhane Medical Faculty, Health Sciences University, Ankara, Turkey https://orcid.org/0000-0001-7538-9119
  • Miraç Özen Department of Medical Oncology, Faculty of Medicine, Sakarya University Sakarya, Turkey https://orcid.org/0000-0002-1934-0190
  • Naziyet Köse Baytemur Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey https://orcid.org/0000-0002-3587-2517
  • Melike Özçelik Department of Medical Oncology, Ümraniye Training And Research Hospital, İstanbul, Turkey https://orcid.org/0000-0003-0406-715X
  • Elif Şahin Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey https://orcid.org/0000-0002-1976-3951
  • Denizcan Güven Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey https://orcid.org/0000-0002-6924-9467
  • Serkan Menekşe Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey https://orcid.org/0000-0002-2134-2128
  • Naziye Ak Department of Medical Oncology, Yozgat City Hospital, Yozgat, Turkey https://orcid.org/0000-0001-5790-7066
  • Fatih Teker Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
  • Engin Kut Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey https://orcid.org/0000-0002-5328-5607
  • Teoman Şakalar Department of Medical Oncology, Kahramanmaraş Necip Fazil City Hospital, Kahramanmaraş, Turkey https://orcid.org/0000-0003-2749-9414
  • Özkan Alan Department of Medical Oncology, Tekirdağ İsmail Fehmi Cumalioğlu City Hospital, Tekirdağ, Turkey https://orcid.org/0000-0002-6635-2012
  • Turgut Kaçan Department of Medical Oncology, Yüksek İhtisas Training And Research Hospital, Health Sciences University Bursa, Bursa, Turkey
  • Nazim Serdar Turhal Department of Medical Oncology, Anadolu Health Center, İstanbul, Turkey https://orcid.org/0000-0002-1013-5676
  • Saadettin Kiliçkap Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey https://orcid.org/0000-0003-1637-7390
  • Sema Türker Department of Medical Oncology, Zonguldak Atatürk State Hospital, Zonguldak, Turkey https://orcid.org/0000-0001-9040-7266
  • Mehmet Ali Nahit Şendur Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0001-7021-6139
  • Osman Köstek Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey https://orcid.org/0000-0002-1901-5603
  • Mustafa Karaağaç Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey https://orcid.org/0000-0003-4533-0620
  • Abdullah Sakin Department of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, Turkey https://orcid.org/0000-0003-2538-8569
  • Haci Mehmet Türk Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University Istanbul, Turkey https://orcid.org/0000-0003-2206-8148
  • Dilek Çağlayan Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey https://orcid.org/0000-0003-4629-6815
  • Şener Cihan Department of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, Turkey
  • Yusuf Açikgöz Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0002-0360-7938
  • Doğan Uncu Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0002-0929-3271

DOI:

https://doi.org/10.17305/bjbms.2021.7069

Keywords:

CF, FOLFOX, gastric cancer, gastroesophageal junction cancer, trastuzumab

Abstract

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, and leucovorin (mFOLFOX)+trastuzumab or cisplatin and fluorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLFOX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (P = 0.495). 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (P = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, P = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, P = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Downloads

Additional Files

Published

16-09-2022

Issue

Section

Translational and Clinical Research

Categories

How to Cite

1.
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Biomol Biomed [Internet]. 2022 Sep. 16 [cited 2024 Mar. 29];22(5):818-25. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069